Doctor Gerardo Sanchez Mejorada Fernandez

Extensive Experience In The Medical Field

Dr. Gerardo Sanchez Mejorada Fernandez's expertise and contributions in clinical medicine, research, and regulatory affairs have had a significant impact on the medical field. He has played crucial roles in drug development, clinical trials, and the launch of various pharmaceutical products, benefiting patients across different therapeutic areas.

A Multifaceted Medical Professional

some key points

  • Education and Medical Specializations

    Dr. Gerardo Sanchez Mejorada Fernandez is an accomplished medical professional with a diverse educational background. He holds an M.D. degree from the prestigious Universidad Nacional Autónoma de México (UNAM). Additionally, he has specialized in internal medicine, infectious diseases, and clinical studies, which has paved the way for his remarkable contributions in the medical field.

  • Extensive Pharmaceutical Leadership

    With over two decades of experience in the pharmaceutical industry, Dr. Gerardo Sanchez Mejorada Fernandez has assumed pivotal roles. From January 2014 to August 2016, he served as the Regional Medical Director for the CardioMetabolic Franchise, overseeing Mexico, Central America, and Andean Countries. Subsequently, he took on the role of Medical Head, Corporate Business, and Clinical Development since August 2016, making significant strides in the organization. His leadership extends beyond this, as he has also held various key positions, including Medical Director and Medical & Regulatory Affairs Director for Stendhal Pharma

  • Clinical Research and Regulatory Expertise

    Dr. Gerardo Sanchez Mejorada Fernandez's dedication to oncology research and patient care sets him apart as a compassionate and innovative medical professional. His tenure as Chief of the Clinical Research Division at the prestigious Instituto Nacional de Cancerología showcased his commitment to advancing cancer treatments. During this period, he played a crucial role in designing and coordinating a multicenter clinical trial in Dyslipidemia, contributing to improved therapeutic approaches for cancer patients.

Featured products